Global sofosbuvir market is expected to grow at a CAGR of around 8.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic hepatitis C infection and rising demand for antiviral drugs. The global sofosbuvir market is segmented on the basis of type, application, and region. On the basis of type, it is classified into ? 98% purity and < 98% purity. On the basis of application, it is classified into 400mg tablets. On the basis of region, it includes North America (US, Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China) and Middle East & Africa (Saudi Arabia). Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase. Sofosbuvir is used in combination with other antiviral agents to treat chronic hepatitis C virus (HCV) genotype 1, 2, 3 or 4 infection.
Industry Growth Insights published a new data on “Sofosbuvir (CAS 1190307-88-0) Market”. The research report is titled “Sofosbuvir (CAS 1190307-88-0) Market research by Types (? 98% Purity, < 98% Purity), By Applications (400mg Tablets, Others), By Players/Companies Teva Pharmaceutical Industries Ltd, DONG BANG FUTURE TECH & LIFE CO., LTD, NIFTY LABS PVT LTD, DEAFARMA, Anhui HaiKang Pharmaceutical Co. Ltd, Haoyuan Chemexpress Co.Ltd, SMS Pharmaceuticals Limited, Beijing Kawin Technology Share-holding Co, Manus Aktteva Biopharma LLP, Hangzhou Longshine Bio-Tech Co, Tecoland, Sinobright Pharmaceutical Company Limited”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sofosbuvir (CAS 1190307-88-0) Market Research Report
By Type
? 98% Purity, < 98% Purity
By Application
400mg Tablets, Others
By Companies
Teva Pharmaceutical Industries Ltd, DONG BANG FUTURE TECH & LIFE CO., LTD, NIFTY LABS PVT LTD, DEAFARMA, Anhui HaiKang Pharmaceutical Co. Ltd, Haoyuan Chemexpress Co.Ltd, SMS Pharmaceuticals Limited, Beijing Kawin Technology Share-holding Co, Manus Aktteva Biopharma LLP, Hangzhou Longshine Bio-Tech Co, Tecoland, Sinobright Pharmaceutical Company Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Sofosbuvir (CAS 1190307-88-0) Market Report Segments:
The global Sofosbuvir (CAS 1190307-88-0) market is segmented on the basis of:
Types
? 98% Purity, < 98% Purity
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
400mg Tablets, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical Industries Ltd
- DONG BANG FUTURE TECH & LIFE CO., LTD
- NIFTY LABS PVT LTD
- DEAFARMA
- Anhui HaiKang Pharmaceutical Co. Ltd
- Haoyuan Chemexpress Co.Ltd
- SMS Pharmaceuticals Limited
- Beijing Kawin Technology Share-holding Co
- Manus Aktteva Biopharma LLP
- Hangzhou Longshine Bio-Tech Co
- Tecoland
- Sinobright Pharmaceutical Company Limited
Highlights of The Sofosbuvir (CAS 1190307-88-0) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ? 98% Purity
- < 98% Purity
- By Application:
- 400mg Tablets
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sofosbuvir (CAS 1190307-88-0) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) protease. Sofosbuvir is approved for the treatment of chronic HCV genotype 1 infection in adults who have failed two or more prior antiviral therapy regimens. Sofosbuvir also has been shown to be effective in treating genotype 3 and 4 HCV infections.
Some of the major players in the sofosbuvir (cas 1190307-88-0) market are Teva Pharmaceutical Industries Ltd, DONG BANG FUTURE TECH & LIFE CO., LTD, NIFTY LABS PVT LTD, DEAFARMA, Anhui HaiKang Pharmaceutical Co. Ltd, Haoyuan Chemexpress Co.Ltd, SMS Pharmaceuticals Limited, Beijing Kawin Technology Share-holding Co, Manus Aktteva Biopharma LLP, Hangzhou Longshine Bio-Tech Co, Tecoland, Sinobright Pharmaceutical Company Limited.
The sofosbuvir (cas 1190307-88-0) market is expected to register a CAGR of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sofosbuvir (CAS 1190307-88-0) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sofosbuvir (CAS 1190307-88-0) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sofosbuvir (CAS 1190307-88-0) Market - Supply Chain
4.5. Global Sofosbuvir (CAS 1190307-88-0) Market Forecast
4.5.1. Sofosbuvir (CAS 1190307-88-0) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sofosbuvir (CAS 1190307-88-0) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sofosbuvir (CAS 1190307-88-0) Market Absolute $ Opportunity
5. Global Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Type
5.3.1. ? 98% Purity
5.3.2. < 98% Purity
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Application
6.3.1. 400mg Tablets
6.3.2. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sofosbuvir (CAS 1190307-88-0) Demand Share Forecast, 2019-2029
9. North America Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Application
9.4.1. 400mg Tablets
9.4.2. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Type
9.7.1. ? 98% Purity
9.7.2. < 98% Purity
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sofosbuvir (CAS 1190307-88-0) Demand Share Forecast, 2019-2029
10. Latin America Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Application
10.4.1. 400mg Tablets
10.4.2. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Type
10.7.1. ? 98% Purity
10.7.2. < 98% Purity
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sofosbuvir (CAS 1190307-88-0) Demand Share Forecast, 2019-2029
11. Europe Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Application
11.4.1. 400mg Tablets
11.4.2. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Type
11.7.1. ? 98% Purity
11.7.2. < 98% Purity
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.101. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sofosbuvir (CAS 1190307-88-0) Demand Share, 2019-2029
12. Asia Pacific Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Application
12.4.1. 400mg Tablets
12.4.2. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Type
12.7.1. ? 98% Purity
12.7.2. < 98% Purity
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sofosbuvir (CAS 1190307-88-0) Demand Share, 2019-2029
13. Middle East & Africa Sofosbuvir (CAS 1190307-88-0) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Application
13.4.1. 400mg Tablets
13.4.2. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sofosbuvir (CAS 1190307-88-0) Market Size and Volume Forecast by Type
13.7.1. ? 98% Purity
13.7.2. < 98% Purity
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sofosbuvir (CAS 1190307-88-0) Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Sofosbuvir (CAS 1190307-88-0) Market: Market Share Analysis
14.2. Sofosbuvir (CAS 1190307-88-0) Distributors and Customers
14.3. Sofosbuvir (CAS 1190307-88-0) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva Pharmaceutical Industries Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. DONG BANG FUTURE TECH & LIFE CO., LTD
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. NIFTY LABS PVT LTD
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. DEAFARMA
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Anhui HaiKang Pharmaceutical Co. Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Haoyuan Chemexpress Co.Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. SMS Pharmaceuticals Limited
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Beijing Kawin Technology Share-holding Co
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Manus Aktteva Biopharma LLP
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hangzhou Longshine Bio-Tech Co
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Tecoland
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sinobright Pharmaceutical Company Limited
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook